{
    "title": "115_hr5687",
    "content": "The Act is titled the \"Securing Opioids and Unused Narcotics with Deliberate Disposal and Packaging Act of 2018\" or the \"SOUND Disposal and Packaging Act.\" It introduces safety-enhancing packaging and disposal features for certain drugs. The Secretary may issue an order requiring the holder of a covered application to implement technologies for drug packaging and disposal to mitigate abuse or misuse, after consulting with stakeholders. The Secretary must consult with stakeholders before issuing an order requiring drug packaging and disposal technologies to prevent abuse. The technologies must be proportionate to the risk of misuse, not overly burdensome on patient access, and consider public health impact. The Secretary must consult stakeholders before issuing an order for drug packaging and disposal technologies to prevent abuse. The order should consider the risk of misuse, patient access, public health impact, and may provide options for implementation. The Secretary may issue orders for implementing technologies, controls, or measures required for drug packaging and disposal. Orders may incorporate standards from recognized organizations for drug classes after consulting stakeholders. The Secretary may issue orders for implementing technologies, controls, or measures required for drug packaging and disposal, including orders applicable to drug classes after consultation with stakeholders. Holders of covered applications must submit proposed changes to comply with such orders within a specified timeframe. The Secretary may issue orders for implementing technologies, controls, or measures required for drug packaging and disposal. Holders of covered applications must submit proposed changes within a specified timeframe. Changes approved in supplements must be implemented within 90 calendar days of approval or a longer period specified by the Secretary. Alternative dates can be requested within 60 calendar days of the order issuance. The Secretary may approve changes in drug packaging and disposal measures within 90 calendar days of supplement approval or a longer period as deemed appropriate. Alternative technologies and controls can be proposed by the holder of the covered application. The holder of the covered application may propose alternative technologies, controls, or measures for packaging, storage, or disposal, supported by data demonstrating their effectiveness in mitigating drug abuse. Disputes can be resolved through a specified process. The holder of a covered application can propose alternative technologies, controls, or measures to mitigate drug abuse, with the ability to appeal any determinations made. The term 'covered application' refers to an application for approval of a drug containing an opioid listed in schedule II or III. 'Relevant stakeholders' may include various experts and entities in the drug industry. The Controlled Substances Act defines 'relevant stakeholders' as experts and entities in the drug industry, including scientific experts, manufacturers, distributors, healthcare providers, and government agencies. Prohibited acts under the Federal Food, Drug, and Cosmetic Act include specific regulations related to opioids. The Drug Enforcement Agency, Medicaid Services, and other relevant stakeholders are involved in regulating drugs under the Federal Food, Drug, and Cosmetic Act. Prohibited acts include regulations related to opioids. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures comparable to those of listed drugs. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures comparable to those of listed drugs. The grounds for refusing to approve an Abbreviated New Drug Application are expanded to include cases where the applicant has not proposed technologies, controls, or measures related to the drug. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures comparable to those of listed drugs. The grounds for refusing to approve an Abbreviated New Drug Application are expanded to include cases where the applicant has not proposed technologies, controls, or measures related to the drug to mitigate abuse or misuse risks. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures comparable to those of listed drugs. Any labeling describing technologies, controls, or measures related to packaging or disposal intended to mitigate the risk of abuse or misuse of a drug product subject to an abbreviated new drug application shall not be construed as changes to labeling not permissible under the Act. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures comparable to those of listed drugs. Any labeling describing technologies, controls, or measures related to packaging or disposal intended to mitigate the risk of abuse or misuse of a drug product subject to an abbreviated new drug application shall not preclude approval of the application. The Federal Food, Drug, and Cosmetic Act is amended to include requirements for Abbreviated New Drug Applications related to opioids, specifically regarding packaging and disposal measures. The Secretary of Health and Human Services may request various data for making determinations under section 505-2. The Comptroller General of the United States will submit a report to Congress within 12 months on the effectiveness of in-home controlled substance disposal products and ways to improve disposal products for patients and consumers. The curr_chunk discusses the effectiveness and availability of in-home controlled substance disposal products and packaging technologies for patients and consumers. It also addresses barriers to their use and federal oversight of these products. The curr_chunk provides a description of Federal oversight of site-of-use, in-home controlled substance disposal products and controlled substance packaging technologies. It includes identification of overseeing agencies, recommended disposal methods, and effectiveness in preventing diversion of prescribed substances. The curr_chunk discusses Federal oversight of controlled substance packaging technologies, including recommended technologies like unit dose packaging. It also addresses the effectiveness of these recommendations in preventing diversion of prescribed substances. The curr_chunk provides recommendations on Federal oversight of in-home controlled substance disposal products and packaging technologies, including which agencies should be responsible for oversight and approval. It also discusses the potential role of the Federal Government in evaluating these products for efficacy. The curr_chunk states that the document was passed by the House of Representatives on June 19, 2018, with Karen L. Haas as the Clerk."
}